Whereas the exploitation of monoclonals for use in diagnostics was rapid (where they have reached the domestic market as components of home pregnancy testing kits), their widespread use in therapy has taken longer to materialiseawaiting the development of methods allowing the production of human or humanised monoclonal antibodies.
Milstein himself was one of the first to spot the benefit that might be reaped by exploiting recombinant DNA technology for the production of engineered antibodies. In his last few years, Milstein was able to see a rapid expansion in the use of monoclonals in therapy -for example, in the treatment of breast cancer, lymphoma and rheumatoid arthritis as well as in the prevention of infection in premature infants. Many other applications are in the pipeline.
Much has been written about the failure to patent monoclonal antibodies. Milstein was keen to protect intellectual property, as well as the interests of the Medical Research Council, in the many areas in which he made discoveries. He did, however, point out that whereas the purpose of patents was to protect intellectual property and thereby permit publication of information allowing the furtherance of the research enterprise, there was nevertheless good reason to believe that the rapid exploitation of monoclonal antibodies had been facilitated by the very fact that they were not patented.
The success of monoclonal antibodies did not cause Milstein to neglect his original interest in antibody diversity. Some of the work on antibody production by myeloma cells was performed in the hope that these cells would exhibit ongoing antibody diversification and therefore permit analysis of the diversification process -a line of approach that was in many ways ahead of its time.
Furthermore, the hybridoma technology itself allowed him to further his original interests. By establishing hybridomas at different stages of an immune response, Milstein and colleagues were able to chart the mutations that accumulate in the immunoglobulin V gene during the course of the response thereby providing a detailed description of antibody affinity maturation.
As the last appointment in his career, Milstein listed 'retired (active) worker' -an enviable situation in which he was (with the assistance of a small group) able to pursue his research interests without administrative responsibilities. And active he remained until the end.
He was developing new diagnostic applications of monoclonal antibodies, was scheduled to examine a PhD dissertation on CD1 and had, within a week of his death, contributed a manuscript for publication on antibody diversification. He certainly followed the advice that I had been given when young -'Leave the party while you are still enjoying it'. The party will obviously continue, greatly saddened by his absence, but with its activities and participants inspired by his multitude of contributions. Where is it found? BDNF is located in specific neuronal populations at low levels in the peripheral nervous system (PNS) and at much higher levels in the central nervous system (CNS). It is most highly expressed in the developing brain, but is still expressed at lower levels in the adult brain. Moreover, expression of BDNF is rapidly and potently regulated by synaptic activity. Where can I find out more?
Michael Neuberger is at the Medical

How does BDNF work?
